89 results about "SUBCUTANEOUS TUMOR" patented technology

The present invention concerns compositions comprising and methods of identification and use of targeting peptides selective for cancer tissue, particularly prostate or ovarian cancer tissue. The method may comprise identifying endogenous mimeotopes of such peptides, such as GRP78, IL-11Rα and hsp90. Antibodies against such targeting peptides or their mimeotopes may be used for detection, diagnosis and/or staging of prostate or ovarian cancer. In other embodiments, the compositions and methods concern novel type of gene therapy vector, known as adeno-associated phage (AAP). AAP are of use for targeted delivery of therapeutic agents to particular tissues, organs or cell types, such as prostate or ovarian cancer. In still other embodiments, targeting peptides selective for low-grade lipomas may be used for detection, diagnosis and targeted delivery of therapeutic agents.

IMDs and methods are provided for electroporation treatment of subcutaneous tumors. In some embodiments, IMDs of the present invention may store and introduce chemotherapy drugs into the body prior to electroporation therapy. High frequency stimulation of tissue in or around the tumor may also be provided to increase tissue temperature prior to electroporation therapy. Still further, delivery of the electroporation therapy may be synchronized with cardiac qRs complex to avoid impeding normal cardiac rhythm. Algorithms to suspend therapy in the event of edema may also be incorporated.

The invention relates to a glutamine metabolic inhibitor-containing liposome and a pharmaceutical composition and use thereof. The fat-soluble glutaminase allosteric site inhibitor and the antitumor activity in combination with other drugs are obviously improved. The pharmacological activity of a glutamine metabolic inhibitor is further enhanced by increasing the solubility of the poorly water-soluble glutamine metabolic inhibitor by a lipophilic part of the liposome and modifying the liposome adjunct such as polymethacrylate; through the screening optimization of a formula, the inhibition rate of tumor cells is increased and finally the preparation is evaluated through an animal subcutaneous tumor model; the experimental results show that the liposome can significantly improve the anti-tumor activity of the glutamine metabolic inhibitor and improve the animal survival rate.

The invention provides a method for constructing a lung tumor experimental animal model. The method comprises the following steps of: 1, feeding a dog with cyclosporin according to the weight ratio of the dog to cyclosporin of 10mg to 1kg 4 days before inoculation; 2, preparing canine transmissible venereal tumor (CTVT) tissue blocks; and 3, puncturing to a predetermined target part by using a 16G guide puncture needle, placing 2 to 3 CTVT tissue blocks into the puncture needle, arranging a sterile gelatin sponge strip behind the CTVT tissue blocks, pushing the tissue blocks into lung tissues by a needle core and pulling the needle out. In the method, CTVT cells are used as tumor strains, the tumor tissue blocks are prepared through subcutaneous tumor cell passage by using the characteristics of transplantability and genetic stability; in-lung planting is performed by a minimally invasive intervention method to establish a dog transplantable lung cancer model; and the model can be applied to related experimental researches such as growth, invasion, transfer and the like of large-sized animal lung tumors.

The invention provides a classification diagnostic kit for liver cancer Sorafenib personalized treatment. Gankyrin overexpression can obviously restrain cell death and subcutaneous tumor proliferation, caused by Sorafenib, but if hydroxychloroquine is combined, drug resistant reaction caused by Gankyrin overexpression is obviously restrained. The classification diagnostic kit can provide new reference for Sorafenib clinical application.

The invention relates to a sciatic nerve ligation subcutaneous tumor-bearing rat model and application of the sciatic nerve ligation subcutaneous tumor-bearing rat model in screening of analgesic and anti-tumor medicine. Single-side sciatic nerve ligation is conducted on an adult Wistar rat subjected to hypodermic implantation of Walker256 tumor cell suspension, the pain degree of the rat is reflected through spontaneous pain, the mechanical pain threshold value and the hot pain threshold value, and the tumor growth situation is indicated through the body weight change, the tumor formation rate and the tumor size of the rat. After the to-be-detected medicine is applied to the animal model according to the required mode and dosage, and the effect of the to-be-detected medicine on the aspect of analgesia and tumor prevention is judged by observing changes of the indexes. The experimental animal model which has the lasting and stable pain characteristic and can visually measure the tumor growth situation of the tumor of the rat is used for exploring the mechanism of promoting tumor growth through pain and used for screening the novel analgesic and anti-tumor medicine. The new carrier is provided for research and development of the novel analgesic and anti-tumor medicine.

The invention discloses a method for inhibiting hepatoma carcinoma nude mouse transplantation tumor capacity through silent secretory clusterin. The method includes the two steps of interference and detection. The method has the advantages that the method is simple and efficient, and it is clearly shown that the silent secretory clusterin can obviously inhibit the human hepatoma carcinoma nude mouse subcutaneous tumor formation capacity. It is effectively shown that the transcription of the silent secretory clusterin prolongs the incubation period of a human hepatoma carcinoma cell tumor-bearing nude mouse model. It is effectively shown that the silent secretory clusterin reduces the hepatoma carcinoma nude mouse transplantation tumor growth speed. Through protein and gene analysis, it is effectively shown that the silent secretory clusterin enables the expression level of the silent secretory clusterin in a hepatoma carcinoma nude mouse transplantation tumor and mRNA of the silent secretory clusterin to be smaller than those of a blank control group and a negative control group.

The invention discloses a human esophageal squamous carcinoma cell line NCCE1 as well as an establishment method and application thereof. The esophageal cancer cell line disclosed by the invention ispreserved in China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: C2020166. The human esophageal squamous carcinoma cell line established by the invention is stable in character, can be stably subcultured, and can induce subcutaneous tumor formation of mice. As a cell and animal model, the model can be directly applied to research and development of anti-cancer drugs and diagnostic reagents, and provides a new experimental material closer to clinical tumor biological characteristics for esophageal squamous cell carcinoma research.

The invention discloses Chinese medicinal ointment for treating hyperthyroidism, scrofula, subcutaneous tumor and mastadenoma and a preparation method thereof. The Chinese medicinal ointment contains raw medicaments such as monkshood, aconite, short-pedicel aconite root, nux vomica, centipede, realgar and potassium nitrate. When the ointment is used, the ointment is directly stuck to a tumor position, a patch is changed every three days, the lump is separated after three to five patches of ointment are stuck, the wound is scared after separation, and the original skin is recovered after the scar is removed, so the scar is not left. The ointment has a good treatment effect on hyperthyroidism, scrofula, subcutaneous tumor, mastadenoma and the like; by adopting an external sticking method, toxic or side effect of an administration method for other Chinese medicaments and defects of various uncomfortable symptoms are well avoided; the ointment has an obvious treatment effect, and does not have toxic or side effect; and a preparation method for the ointment is easy to operate, the content of active ingredients is high, and the making cost is low.

The locally applied medicine composition for treating subcutaneous tumor includes As2O3 in effective amount and pharmaceutically acceptable carrier. It is used in treating primary skin cancer, melanin cancer or metastatic subcutaneous cancer.

The invention relates to an optical-image-based non-invasive naked mouse tumor receptor density determining method. Receptor detection expressing means and methods in existing scientific experiments can be only used for qualitative or half quantitative measurement but cannot calculate receptor density values accurately. The method includes the steps of 1, establishing a naked mouse subcutaneous tumor model; 2, injecting an optical mark target probe to perform dynamic optical acquisition; 3, marking an ROI (region of interest); 4, performing singular value decomposition; 5, fitting data to obtain a BP value; 6, calculating an available receptor density. The optical-image-based non-invasive naked mouse tumor receptor density determining method is a method by which available receptor density information of tumor regions can be obtained without obtaining living tissues invasively, thereby being simpler and more convenient and accurate than previous methods.

The invention discloses a combined drug for treating colorectal cancer. The combined drug is prepared from diosgenin, baicalein A, fucoidan and psoralen. An in-vivo animal experiment shows that the combination application of the diosgenin, the baicalein A, the fucoidan, the psoralen, Binimetinib and cetuximab has a significant synergistic effect on the treatment of the colorectal cancer, the diosgenin can affect the blood supply of tumor by inhibiting the proliferation activity of endothelial cells, and finally inhibit the proliferation of a subcutaneous tumor model, meanwhile, the diosgenin can inhibit the metastasis of rectal cancer through the direct action, and has the synergistic interaction effect by combining with the cetuximab; and the purpose of tumor prevention can be achieved bythe psoralen through multiple mechanisms of calcium antagonistic effect, multi-drug resistance reversing effect, estrogen-like effect, photosensitive activity effect, apoptosis inducing , mitochondrial degeneration inducing and the like.

The invention discloses application of macrocarpal I to preparation of an anti-tumor drug. In an experiment, the inventor finds that the macrocarpal I can effectively inhibit proliferation in vitro orinvasion of colorectal cancer cells, can inhibit the clonality of the colorectal cancer cells, can reduce the growth rate of the subcutaneous tumor of a naked mouse and has certain specificity to thecolorectal cancer cells. In addition, the macrocarpal I is extremely high in safety and expected to be a natural anti-tumor micro-molecular compound applied to the treatment of the metastatic colorectal cancer.

The invention discloses a circular RNA (Ribonucleic Acid) and application thereof. The cDNA (complementary deoxyribonucleic acid) sequence of the circular RNA is disclosed by SEQ ID NO:1, and the structure of the circular RNA is an end-to-end circular structure formed in a way that a nucleotide sequence disclosed by SEQ ID NO:1 is sheared after transcription is carried out. Through QPCR (quantitative polymerase chain reaction), an expression difference situation of circDLC1 in hepatocellular carcinoma tissues and para-carcinoma tissues is detected so as to discover that the expression of the circDLC1 in the hepatocellular carcinoma tissues is obviously lowered than the expression in the para-carcinoma tissues, and the circDLC1 can be indicated to be used for hepatocellular carcinoma diagnosis. A migration and invasion experiment can prove that after the circDLC1 is subjected to overexpression, hepatocellular carcinoma cell migration and invasion ability is obviously inhibited so as toindicate that the circDLC1 can be used as a treatment target spot for diagnosing and treating the hepatocellular carcinoma cells; and a naked mouse subcutaneous tumor model, a naked mouse hepatocellular carcinoma in situ model and a naked mouse advanced stage transferring model are constructed to prove that circDLC1 overexpression has an inhibition function for proliferation, invasion and transferof hepatocellular carcinoma cells in the body of the naked mouse.

The invention provides an application of PPM-18 in inducing apoptosis of bladder cancer cells by activating intracellular reactive oxygen species (ROS). The PPM-18 significantly inhibits the viabilityof bladder cancer cell; PPM-18 promote cell apoptosis by inducing ROS production in bladder cancer cells; and the PPM-18 significantly inhibits the growth of human bladder cancer subcutaneous tumorsand prolongs the survival cycle of mice with subcutaneous tumors. At the same time, PPM-18 has very lower toxicity to normal human hepatocyte. In addition, PPM-It can be synthesized chemically, with lower cost, and can be used as a new drug for treating bladder cancer.

The invention belongs to the technical field of pharmacy, and relates to a novel pharmaceutical application of cinobufotalin, in particular to application of the cinobufotalin in preparation of an anti-tumor immune drug. Mouse colon cancer subcutaneous transplantation tumor model animal experiments prove that the cinobufotalin has a good effect on resisting tumor immunity, has no adverse reaction, can relieve mouse colon cancer subcutaneous tumor induced by colon cancer cells, and provides a good application prospect for treating, relieving or eliminating tumor immune escape and improving body immunity.

The invention relates to the technical field of biomedical materials, in particular to a double-layer conductive microneedle patch for treating subcutaneous tumors and a preparation method and application thereof.The double-layer conductive microneedle patch is composed of a conductive microneedle substrate without a target drug and a double-layer microneedle tip containing the target drug, and the microneedle tip is prepared from an easily-soluble polymer matrix; the micro-needle substrate and the part, close to the substrate, of the micro-needle tip are prepared from a degradable polymer matrix and a conductive polymer material, so that the micro-needle has excellent biocompatibility and has no potential irritation and immunogenicity; the substrate and the part, close to the substrate, of the microneedle tip are made of a conductive polymer material, so that good conductivity is achieved, cell membrane permeability is improved through electroporation, and the biological agent or medicine absorption rate is increased; the proliferation of tumor cells is effectively inhibited; through the microneedle technology, target medicine can be intensively distributed at the tip of the microneedle, the local effective medicine concentration is improved, and the medicine cost is saved; the method has the advantages of high precision, large scale, economy and high efficiency.